200 related articles for article (PubMed ID: 37282614)
1. Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Xu K; Gao B; Li J; Xiang Y; Cao L; Zhao M
Hum Vaccin Immunother; 2023 Aug; 19(2):2220630. PubMed ID: 37282614
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Joo CW; Kim YK; Park SP
Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
[TBL] [Abstract][Full Text] [Related]
3.
Brunet de Courssou JB; Tisseyre M; Hadjadj J; Chouchana L; Broca F; Terrier B; Duraffour P; Henriquez S
Ocul Immunol Inflamm; 2022 Jul; 30(5):1292-1295. PubMed ID: 35113742
[TBL] [Abstract][Full Text] [Related]
4. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
6. A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Dutta Majumder P; Sadhu S; González-López JJ; Mochizuki M
Indian J Ophthalmol; 2023 Jun; 71(6):2587-2591. PubMed ID: 37322685
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.
Muto T; Sakamoto M; Imaizumi S; Kamoi K
J Int Med Res; 2024 Jan; 52(1):3000605231221081. PubMed ID: 38170955
[TBL] [Abstract][Full Text] [Related]
8. Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
Rujkorakarn P; Patamatamkul S
J Fr Ophtalmol; 2023 Mar; 46(3):207-210. PubMed ID: 36775731
[TBL] [Abstract][Full Text] [Related]
9. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.
Zhao C; Dong F; Gao F; Liu X; Pei M; Jia S; Zhang M
BMC Ophthalmol; 2018 Jan; 18(1):6. PubMed ID: 29334924
[TBL] [Abstract][Full Text] [Related]
11. Annular choroidal detachment in a patient with Vogt-Koyanagi-Harada disease.
Yamamoto N; Naito K
Graefes Arch Clin Exp Ophthalmol; 2004 Apr; 242(4):355-8. PubMed ID: 14963715
[TBL] [Abstract][Full Text] [Related]
12. De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy.
Yamaguchi C; Kunikata H; Hashimoto K; Yoshida M; Ninomiya T; Hariya T; Abe T; Nakazawa T
Am J Ophthalmol Case Rep; 2022 Sep; 27():101616. PubMed ID: 35719316
[TBL] [Abstract][Full Text] [Related]
13. Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.
Sato T; Nihei R; Sora D; Nishio Y; Takeuchi M
Front Immunol; 2022; 13():967972. PubMed ID: 36248859
[TBL] [Abstract][Full Text] [Related]
14. Pseudo-inflammatory manifestations of choroidal lymphoma resembling Vogt-Koyanagi-Harada disease: case report based on multimodal imaging.
Fukutsu K; Namba K; Iwata D; Mizuuchi K; Kase S; Suzuki K; Shimizu H; Shibata Y; Yamawaki F; Onozawa M; Ishida S
BMC Ophthalmol; 2020 Mar; 20(1):94. PubMed ID: 32156266
[TBL] [Abstract][Full Text] [Related]
15. Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.
Zou H; Zhang K; Chen X; Sha S
Immun Inflamm Dis; 2024 Apr; 12(4):e1250. PubMed ID: 38661242
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for subretinal fibrosis in patients with Vogt Koyanagi Harada syndrome.
Golzarri MF; Cheja-Kalb R; Concha-Del-Río LE; Gonzalez-Salinas R; Arellanes-García L
Ocul Immunol Inflamm; 2022 Feb; 30(2):265-269. PubMed ID: 33021860
[TBL] [Abstract][Full Text] [Related]
18. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
Koong LR; Chee WK; Toh ZH; Ng XL; Agrawal R; Ho SL
Ocul Immunol Inflamm; 2021 Aug; 29(6):1212-1215. PubMed ID: 34505819
[TBL] [Abstract][Full Text] [Related]
19. Clinical and therapeutic features of pediatric Vogt-Koyanagi-Harada disease.
Albaroudi N; Tijani M; Boutimzine N; Cherkaoui O
J Fr Ophtalmol; 2020 May; 43(5):427-432. PubMed ID: 32115269
[TBL] [Abstract][Full Text] [Related]
20. Acute-onset Vogt-Koyanagi-Harada like uveitis following Covid-19 inactivated virus vaccination.
Chen X; Wang B; Li X
Am J Ophthalmol Case Rep; 2022 Jun; 26():101404. PubMed ID: 35165663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
